Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CABINET: Cabozantinib Versus Placebo in Advanced Neuroendocrine Tumors
NCT03375320Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2018
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cabozantinib in Neuroendocrine Neoplasm (NEN), sponsored by National Cancer Institute. Started Oct 2018; status: active, not recruiting.
02
Drugs
cabozantinib
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT03375320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03375320.